Novo Nordisk's next generation weight loss drug CagriSema matches Lilly's Zepbound in major trial, but doesn't surpass it CNN Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial ScienceDirect Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity New England Journal of Medicine Novo Next Generation Obesity Shot Falls Short of Lilly Rival Bloomberg Novo Nordisk advances obesity candidate to late stage program after weight loss of less than 12%